<DOC>
	<DOCNO>NCT00784927</DOCNO>
	<brief_summary>RATIONALE : Lenalidomide may stop growth cancer cell block blood flow cancer . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving lenalidomide together rituximab , cyclophosphamide , dexamethasone may kill cancer cell . PURPOSE : This phase II trial study well give lenalidomide together rituximab , cyclophosphamide , dexamethasone work treat patient previously untreated low-grade non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Lenalidomide , Rituximab , Cyclophosphamide , Dexamethasone Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess tumor response lenalidomide , rituximab , cyclophosphamide , dexamethasone patient symptomatic previously untreated low-grade non-Hodgkin lymphoma . Secondary - To describe adverse event profile regimen . - To evaluate overall survival , progression-free survival , duration response , time treatment failure associate regimen . - To estimate tumor response lenalidomide , rituximab , cyclophosphamide dexamethasone subgroup patient lymphoplasmacytic lymphoma ( Waldenstrom 's macroglobulinemia ) . OUTLINE : This multicenter study . Patients receive oral lenalidomide daily day 1-21 , rituximab IV day 1 , oral cyclophosphamide daily day 1 , 8 , 15 , oral dexamethasone daily day 1 , 8 , 15 , 22 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm symptomatic nonHodgkin lymphoma biopsy within past 6 month Any follow subtypes allow : Grade 1 2 lymphoma Small lymphocytic lymphoma Marginal zone lymphoma Lymphoplasmacytic lymphoma ( Waldenstrom macroglobulinemia [ WM ] ) Previously untreated disease , investigator 's opinion , require treatment Measurable disease CT MRI scan lymph node ≥ 2.0 cm ≥ 1 dimension WM patient without lymphadenopathy must meet following criterion : More 10 % lymphocyte , lymphoplasmacytic cell , plasma cell bone marrow aspirate/biopsy Quantitative Immunoglobulin M ≥ 400 mg/dL NOTE : A new classification scheme adult nonHodgkin lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,400/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 2.0 mg/dL Total direct bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2 time upper limit normal ( ULN ) ( 5 time ULN hepatic metastasis present ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception least 28 day prior , , 28 day completion study therapy Able take acetylsalicylic acid ( ASA ) 325 mg/day prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) No know hypersensitivity thalidomide No development erythema nodosum characterize desquamating rash take thalidomide similar drug No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure require use ongoing maintenance therapy lifethreatening ventricular arrhythmia Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement No myocardial infarction within past 6 month No active malignancy require treatment , except localize nonmelanomatous skin cancer cancer , judgement investigator , treat curative intent interfere study treatment plan response assessment No comorbid systemic illness severe concurrent disease , judgement investigator , would make patient inappropriate entry study would interfere significantly proper assessment safety toxicity study treatment No known positivity HIV infectious hepatitis A , B , C No serious medical condition , laboratory abnormality , psychiatric illness would prevent patient signing informed consent Willing return Mayo Clinic enrol institution follow Registered RevAssist® program willing able comply requirement RevAssist® PRIOR CONCURRENT THERAPY : No prior lenalidomide No prior irradiation ≥ 25 % bone marrow More 28 day since prior experimental drug therapy No concurrent radiotherapy , chemotherapy , immunotherapy No concurrent anticancer agent treatment , include thalidomide investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>